Brian with the Good Dictations
@ghoshhajra
Father. Doctor. Radiologist. CV Imager. Not a robot. Assoc Chair, Operations Analytics, Academic Director, Div CV Imaging @mghimaging & Past Pres @Heart_SCCT
ID:96387316
https://www.massgeneral.org/imaging/approach/clinical-divisions/cardiovascular 12-12-2009 17:56:21
4,6K Tweets
3,2K Followers
3,0K Following
Out today in JAMA, in this Viewpoint available with free access, Jason H. Wasfy, M.D., James Januzzi Jr MD, and I pose the question:
Is Myocardial Infarction Overdiagnosed?
jamanetwork.com/journals/jama/…
Amazing grand rounds today by one and only Dr Andrew D. Choi AI in CCTA Brian with the Good Dictations Sandeep Hedgire Nina Meyersohn MGH Radiology Chiefs Ron Blankstein Cian McCarthy Vinit Baliyan MGH Cardiovascular Imaging Research Center BorekFoldyna Giselle A. Suero Abreu, MD PhD Mass General Heart MGH Cardiology Fellows Heart_SCCT
Energized to serve as Visiting Professor at Mass General Imaging MGH Radiology Chiefs @circ_mgh this year!
With #YesCCT now front line in guidelines, the field is just getting started - #AI /ML, #PlaqueImaging , prevention, education, expanding access, policy & new plaque trials are the new
Congratulations CVPath Institute Inc Founder & President
🎉Dr. Renu Virmani 🎉
and thank you for your work, which has revolutionized our understanding of #coronary #atherosclerotic plaques + their role in sudden coronary death.
#cardiovasculardisease
Learn more 🏆scct.org/page/AgatstonA…
Super excited about the Technologist Perspective series of the podcast 🔊 kudos Nikki Weber for being our esteemed guest!
Listeners, #YesCCT tech-related topics you wanna hear about? Injection prtcls, lead plcmnt, breath instruct, 3D lab creation? donutofdestiny.buzzsprout.com/874432/14721011
The Cardiovascular Performance Program MassGeneral News has been at the forefront of sports cardiology since 2009. Our fellowship has generated over a dozen sports cardiologists across N. America. Please RT & encourage your brightest to apply for '25-'26!
bit.ly/3VmPfv2
Primary results of REPRIEVE Trial mechanistic substudy:
· Pitavastatin ⬇️nonca coronary plaque 7% and plaque progression 33%.
· ⬇️lipid oxidation and arterial inflammation
· Helps explain 35% ⬇️MACE in REPRIEVE.
bit.ly/3UlsBCy